Condition
End Stage Heart Failure
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 3 (1)
Trial Status
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03356353Phase 3UnknownPrimary
Sildenafil for the Prevention of Right Heart Failure Following LVAD Implantation
NCT03923413CompletedPrimary
Endothelial Function and Circulating Microparticle in Patients Under LVAD Support
NCT02174133CompletedPrimary
Impact of LVAD Implantation on Micro- and Macrovascular Function
Showing all 3 trials